China Atorvastatin Market Report 2021 With Pfizer, Lepu Medical Technology, Beijing Jialin Pharmac, Qilu Pharma, Fujian Dawnrays Pharma
Dublin, Aug 13, 2021 (GLOBE NEWSWIRE) – The “Investigation Report on China’s Atorvastatin Market 2021-2025” has been added to ResearchAndMarkets.com offer.
The analyst expects that with effective relief from COVID-19, the sales value of atorvastatin in the Chinese market will experience restorative growth from 2021 to 2025.
Atorvastatin is a statin used to lower blood cholesterol levels. This common medicine is mainly used to treat high cholesterol, hyperlipidemia and coronary heart disease. The original drug Atorvastatin was developed by Pfizer Pharmaceuticals under the trade name LIPITOR. According to the analysis, Lipitor entered the Chinese market in 1999, then the generic drugs of some Chinese local companies were successively listed. Pfizer Pharmaceuticals still represents the largest market share in China by 2020.
According to the analyst’s market research, the sales value of atorvastatin in the Chinese market increased from 2016 to 2018. In 2019, due to its inclusion in the Chinese government’s “4 + 7” policy for centralized supply of drugs, the price of the drug fell. sharply, resulting in an 18.33% year-over-year decline in the value of its sales. In 2020, due to the impact of COVID-19 on all hospital diagnostic and treatment departments, the sales value of atorvastatin in the Chinese market in 2020 fell to CNY 825 million and the CAGR is around -20.30% from 2016 to 2020.
In addition, the Seventh Census showed that at the end of 2020, the total population of China was 1,411.78 million, and the population aged 60 and over was 264.02 million, or 18.70% of the total population. The elderly population in China is expected to show an increasing trend. The proportion of the elderly population will continue to increase and the incidence of cardiovascular disease will continue to increase accordingly.
In addition, as the pace of life of Chinese residents accelerates, unhealthy lifestyles increase the risk of blood lipid diseases and expand the market for atorvastatin. Therefore, the analyst predicts that the sales value of atorvastatin in the Chinese market will continue to grow from 2021 to 2025.
Main topics covered:
1 Relevant concepts of atorvastatin
1.1 Indications for atorvastatin
1.2 Development of atorvastatin in China
1.3 Government approval of atorvastatin in China
1.4 The impact of COVID-19 on atorvastatin sales in China
2 Atorvastatin Sales in China, 2016-2020
2.1 Atorvastatin Sales Value
2.1.1 Overall value of sales
2.1.2 Sales Value by Regions
2.2 Atorvastatin Sales Volume
2.2.1 Global sales volume
2.2.2 Sales Volume by Regions
2.3 China Atorvastatin Sales by Dosage Form, 2016-2020
2.3.1 Dispersible tablets
3 China Major Atorvastatin Manufacturers Analysis, 2016-2020
3.1 Major Manufacturers of Atorvastatin Market Share Analysis
3.1.1 Market Share by Sales Value Survey
3.1.2 Market Share by Sales Volume Survey
3.2 Pfizer Inc
3.2.1 Company profile
3.2.2 Sales of LIPITOR (Atorvastatin by Pfizer Inc) in China
3.3 Lepu Medical Technology Co., Ltd.
3.3.1 Company profile
3.3.2 Sales of Youliping (Atorvastatin by Lepu Medical Technology Co., Ltd.) in China
3.4 Beijing Jialin Pharmaceutical Co., Ltd.
3.4.1 Company profile
3.4.2 Sales of Ale (Atorvastatin from Beijing Jialin Pharmaceutical Co., Ltd.) in China
3.5 Qilu Pharmaceutical (Hainan) Co., Ltd.
3.5.1 Company Profile
3.5.2 Sales of Meidaxin (Atorvastatin by Qilu Pharmaceutical (Hainan) Co., Ltd.) in China
3.6 Fujian Dawnrays Pharmaceutical Co., Ltd.
3.6.1 Company Profile
3.6.2 Anweining (Atorvastatin from Fujian Dawnrays Pharmaceutical Co., Ltd.) Sales in China
4 Atorvastatin Price for Different Manufacturers in China, 2020-2021
4.1 Pfizer Inc (LIPITOR)
4.2 Lepu Medical Technology Co., Ltd. (Youliping)
4.3 Beijing Jialin Pharmaceutical Co., Ltd. (Ale)
4.4 Qilu Pharmaceutical (Hainan) Co., Ltd. (Meidaxin)
4.5 Fujian Dawnrays Pharmaceutical Co., Ltd. (Anweining)
5 China Atorvastatin Market Outlook, 2021-2025
5.1 Factors influencing the development of the Chinese market for atorvastatin
5.1.1 The impact of COVID-19 on the Chinese atorvastatin market
5.1.2 Market Drivers and Opportunities
5.1.3 Market threats and challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
Lepu Medical Technology Co., Ltd.
Beijing Jialin Pharmaceutical Co., Ltd.
Qilu Pharmaceutical (Hainan) Co., Ltd.
Fujian Dawnrays Pharmaceutical Co., Ltd.
For more information on this report, visit https://www.researchandmarkets.com/r/gtjmc4
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900